March 19, 2002
Ms. Janet L. Fisher, Esq.
Re: Biotech BOXES
Dear Ms. Fisher:
In your letter dated March14, 2002, as supplemented by conversations with the staff, you request exemptions from Rules 10a-1 and 14e-5 under the Securities Exchange Act of 1934 ("Exchange Act"). You seek these exemptions on behalf of Morgan Stanley Dean Witter & Co. ("MSDW"), the American Stock Exchange LLC ("AMEX"), the Philadelphia Stock Exchange, Inc. ("PHLX"), the Biotech Basket Opportunity Exchangeable Securities series ("BOXES"), and other persons or entities engaging in market transactions in BOXES on the AMEX and the PHLX.1 We have attached a copy of your letter to avoid reciting the facts that it presents. Unless otherwise noted, each defined term in this letter has the same meaning as in your letter.
Rule 3b-3 defines the term "short sale" and Rule 10a-1 governs short sales generally. Rule 10a-1 covers transactions in any security registered on a national securities exchange, and it prohibits short sales in these securities unless such sales occur on a "plus tick" (i.e., at a price above the price at which the immediately preceding sale was effected) or a "zero-plus tick" (i.e., at the last sale price if it was higher than the last different sale price). Rule 10a-1 is designed to prevent the market price of a stock or other "reported security," as defined in paragraph (a)(4) of Rule 11Aa3-1 under the Exchange Act, from being manipulated downward by unrestricted short selling.
On the basis of your representations and the facts presented, we do not believe that trading in BOXES would be susceptible to the abuses that Rule 10a-1 is designed to prevent. In particular we have relied upon your representations that:
(1) BOXES are senior debt securities issued by MSDW exchangeable for a cash amount based on the reported market prices of a portfolio of common stocks replicating the seventeen component stocks of the AMEX Biotechnology Index (the "Underlying Stocks");2
(2) the market price of the BOXES will rise or fall based almost entirely on changes in the values of the Underlying Stocks;
(3) each Underlying Stock is actively traded within the meaning of the exception for actively-traded securities set forth in Rule 101(c)(1) of Regulation M;
(4) the BTK Index is an equal-dollar weighted index; and
(5) the initial weightings of each of the Underlying Stocks will represent an equal percentage of the total value of the BTK Index, and with each quarterly rebalancing of the BTK Index, the Underlying Stocks' proportionate weightings will be adjusted as necessary to retain equal concentrations of Underlying Stocks.3
Accordingly, the Commission hereby grants an exemption from Rule 10a-1 to permit short sales of BOXES without regard to the "tick" requirements of Rule 10a-1. We note that the exemption from Rule 10a-1 would not apply to secondary market sales of the Underlying Stocks.
Rule 14e-5 under the Exchange Act, among other things, prohibits any covered person in connection with a tender offer for equity securities from, directly or indirectly, purchasing or arranging to purchase any subject or related securities (collectively, "Covered Securities") except as part of the offer, from the time the offer is publicly announced until its expiration. Rule 14e-5 explicitly includes dealer-managers of a tender offer within the rule's definition of covered person. Accordingly, while acting as dealer-manager of a tender offer for an Underlying Stock, a dealer-manager is prohibited from purchasing or arranging to purchase that Underlying Stock until the expiration of the offer.
You request an exemption from Rule 14e-5 to allow a dealer-manager and its affiliates4 (including a member or member organization of the AMEX or the PHLX), to make purchases and arrangements to purchase Covered Securities in the ordinary course of business and solely to offset sales of the Pharmaceutical BOXES (including subsequent issuances of BOXES) pursuant to bona fide hedging and covering activities. On the basis of your representations and the facts presented, purchases of Covered Securities in these circumstances would not appear to result in the abuses which Rule 14e-5 is directed. In particular, we are relying on your representations that:
(1) MSDW and its affiliates will maintain and enforce written policies and procedures reasonably designed to prevent the flow of information to or from the persons engaged in the trading activities involving Covered Securities that might result in a violation of the federal securities laws and regulations with respect to the BOXES or the Underlying Stocks;
(2) any trading activities with Covered Securities will be effected in the ordinary course of business and not for the purpose of facilitating any offer, including specifically that shares obtained by MS&Co. and/or other affiliates of MSDW as a result of the trading activities in Covered Securities will not be tendered into any offer;
(3) no purchases or arrangements to purchase any Covered Securities as part of the trading activities will be made directly or indirectly on behalf of the offeror;
(4) except as otherwise exempted by the Commission, MSDW and its affiliates will comply with Rule 14e-5.
The Commission hereby grants an exemption from Rule 14e-5 to permit MSDW and its affiliates (including a member or member organization of the AMEX or the PHLX) acting as dealer-manager of a tender offer for an Underlying Stock to purchase such Underlying Stock for bona fide hedging and covering activities, as described in your letter.
You have not asked for relief from, and we have not addressed, the requirements of Regulation M with regard to any distribution of BOXES. The foregoing exemptions under Rules 10a-1 and 14e-5 are based solely on your representations and the facts presented, and are strictly limited to the application of these rules to the proposed transactions. In the event that any material change occurs with respect to any of the facts or representations you have made, such transactions should be discontinued, pending our reconsideration. Furthermore, the exemptions from Rules 10a-1 and 14e-5 are subject to the condition that such transactions in BOXES, any Underlying Stock, or any related securities, are not made for the purpose of creating actual or apparent active trading in, or raising or otherwise affecting the price of, such securities.
These exemptions are subject to modification or revocation if at any time the Commission determines that such action is necessary or appropriate in furtherance of the purposes of the Exchange Act. In addition, persons relying on these exemptions are directed to the anti-fraud and anti-manipulation provisions of the federal securities laws, including Sections 9(a) and 10(b) of the Exchange Act, and Rule 10b-5 thereunder. Responsibility for compliance with these and any other provisions of the federal and state securities laws rests with those individuals relying on this exemption. The Division expresses no view with respect to any other questions that the proposed transactions may raise, including, but not limited to, the adequacy of disclosure concerning BOXES and the applicability of other federal and state laws to the proposed transactions.
For the Commission, by the
Division of Market Regulation,
James A. Brigagliano
[Letterhead of Cleary, Gottlieb, Steen & Hamilton]
March 14, 2002
Confidential Treatment Requested by Morgan Stanley Dean Witter & Co.
Mr. James A. Brigagliano
Securities and Exchange Commission
Re: Request for Exemptive, Interpretive or No-Action Relief from Rules 10a-1 and 14e-5 under the Securities Exchange Act of 1934
Dear Mr. Brigagliano:
Morgan Stanley Dean Witter & Co. ("Morgan Stanley Dean Witter"), by its undersigned counsel, hereby requests relief from Rules 10a-1 and 14e-5 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in connection with market transactions in its Basket Opportunity eXchangeablE SecuritiesSM, or "BOXESSM" (the "BOXES"), on behalf of itself, the Philadelphia Stock Exchange, Inc. (the "Phlx"), The American Stock Exchange LLC (the "Amex") and persons or entities engaging in market transactions in respect of a specified series of BOXES as described below.1 The relief requested by this letter is substantially similar to the relief previously granted by the staff (the "Staff") of the Division of Market Regulation of the Securities and Exchange Commission (the "Commission") with respect to Morgan Stanley Dean Witter's Pharmaceutical BOXES.2
Description of BOXES
BOXES are senior debt securities issued by Morgan Stanley Dean Witter in one or more series. Each series will be exchangeable for a cash amount based on the reported market prices of a portfolio of common stocks (the "Underlying Stocks") upon:
Each series of BOXES is expected to pay a quarterly base coupon equal to the distributions, if any, paid on the Underlying Stocks and an annual supplemental coupon at a rate based on the adjusted average daily closing values of the Underlying Stocks during a prescribed period.
BOXES are intended to provide investors with a debt security, issued by a highly-rated issuer, that is exchangeable for the cash value of the Underlying Stocks. Specifically, each series of BOXES is intended to allow investors to:
Morgan Stanley Dean Witter anticipates that additional issuances of a particular series of BOXES will be made subsequent to the initial issuance of that series (and prior to the maturity of the notes of that series) for purposes of providing market liquidity. Subsequent issuances of a series will have identical terms, other than price. The offering price of any reopening of a series of BOXES will be derived from the value of the Underlying Stocks as of the applicable pricing date, plus accrued but unpaid coupon amounts and the applicable agent's or underwriter's discounts and commissions.
Investors may purchase BOXES either in the initial placement or in the secondary market. Although an investor may generally exchange BOXES for the cash value of the Underlying Stocks prior to maturity only in a specified minimum amount of BOXES (and multiples of 100 in excess thereof, subject to a special exception in the event of a ratings downgrade of Morgan Stanley Dean Witter), secondary market transactions in the BOXES may be in round lots (100 BOXES) or odd lots. The BOXES will be issued in book-entry form only. Morgan Stanley & Co. Incorporated, a wholly-owned subsidiary of Morgan Stanley Dean Witter and a broker-dealer registered as such under the Exchange Act ("MS & Co."), will act as the underwriter or placement agent in connection with each series of BOXES. MS & Co. intends to make a market in the BOXES.
Description of the Biotech BOXES and the Amex Biotechnology Index
Morgan Stanley Dean Witter, on behalf of itself, the Amex, the Phlx and persons engaging in market transactions in the Biotech BOXES, is requesting the relief described herein solely with respect to such Biotech BOXES. The Biotech BOXES will be exchangeable in minimum amounts of 30,000 Biotech BOXES3 for an amount in cash based on the reported market prices of the common stock of the biotechnology companies underlying the Amex Biotechnology Index (the "BTK Index"), an index that has been approved by the Commission under Section 19(b)(2) of the Exchange Act.4 The Biotech BOXES will be issued under an effective registration statement filed with the Commission under the Securities Act of 1933, as amended, with respect to Morgan Stanley Dean Witter's debt securities.
The BTK Index is an equal-dollar weighted index (i.e., each of the Underlying Stocks is represented in approximately equal dollar amounts in the index) currently based on 17 U.S. Underlying Stocks that represent a cross-section of the biotechnology industry and that are traded on the New York Stock Exchange or through the facilities of Nasdaq as National Market Securities.5 The value of the BTK Index was initially calculated by (i) determining the number of shares (to the nearest whole share) that represented $10,000 of each Underlying Stock at their closing prices on October 18, 1991; (ii) multiplying the resulting number of shares for each Underlying Stock by the closing price for that Underlying Stock on October 18, 1991; (iii) calculating the sum of all those products; and (iv) dividing such sum by a divisor (the "Divisor") which established a base value for the Index. Because each Underlying Stock was initially represented in approximately an equal dollar amount in the Index, each Underlying Stock initially represented an equal percentage of the weight of the Index.
Based on publicly available information, we understand that the value of the BTK Index at any time will equal the aggregate market value (based on U.S. primary market prices) of the assigned number of shares of each Underlying Stock divided by the Divisor. Accordingly, the weightings of the Underlying Stocks in the Index will change as their prices change. Each quarter, following the close of trading on the third Friday of January, April, July and October, the Amex adjusts the number of shares of each Underlying Stock so that the number of shares of each Underlying Stock again represents an equal dollar amount of each stock. Each Underlying Stock therefore again represents an equal percentage (so long as the BTK Index is comprised of 17 Underlying Stocks, 5.88%) of the weight of the Index. If necessary, the Amex will adjust the Divisor to ensure continuity of the BTK Index's value.6 The adjusted portfolio will become the basis for the BTK Index's value on the first trading day following the quarterly adjustment.
We further understand that the number of shares of each Underlying Stock will remain fixed between quarterly adjustments except in the event of certain types of corporate actions, such as the payment of a dividend (other than an ordinary cash dividend), stock distributions, stock splits, reverse stock splits, rights offerings, or a distribution, reorganization, recapitalization or similar events with respect to an Underlying Stock. The number of shares of an Underlying Stock will also be adjusted in the event of a merger, consolidation, dissolution or liquidation with respect to the issuer of that stock. When such adjustments occur between quarterly adjustments, the number of shares of the relevant Underlying Stock will be adjusted, to the nearest whole share, to maintain its relative weight in the BTK Index at the level immediately prior to the event giving rise to the adjustment. If an Underlying Stock is replaced, the average value of the remaining Underlying Stocks is calculated and the resulting amount will be invested (to the nearest whole share) in the new Underlying Stock. In both cases, the Divisor will be adjusted, if necessary, to ensure the continuity of the BTK Index's value.
All of the Underlying Stocks included in the BTK Index must be equity securities registered under Section 12 of the Exchange Act and are and must be listed for trading on the New York Stock Exchange or the Amex or quoted on and traded through the Nasdaq National Market System. Accordingly, all of the Underlying Stocks included in the BTK Index are subject to real-time last sale reporting under Rule 11Aa3-1 under the Exchange Act.
The BTK Index is calculated and published by the Amex. The Amex may change the BTK Index from time to time, subject to compliance with the maintenance criteria set forth in the Section 19(b)(2) order of the Commission that approved the BTK Index for options trading. The Phlx and the Amex plan to list the Biotech BOXES for trading pursuant to Rule 19b-4(e)(1) under the Exchange Act.7
Rule 10a-1(a)(1)(i) under the Exchange Act provides that a short sale of an exchange-traded security may not be effected below the last regular-way sale price, or at such price unless such price is above the next preceding different price at which a sale was reported. A primary purpose of Rule 10a-1 is to prevent the market price of a stock from being manipulated downward by unrestricted short selling.
Application of Rule 10a-1 to the Biotech BOXES will not further the Rule's purpose. As noted above, the Commission previously has granted exemptive relief from Rule 10a-1 with respect to the first series of BOXES, the Pharmaceutical BOXES.8 As with the Pharmaceutical BOXES, Morgan Stanley Dean Witter anticipates that the market price of the Biotech BOXES will rise or fall based almost entirely on changes in the value of the Underlying Stocks. The market price of the Biotech BOXES should therefore not decline absent a decline in the value of the Underlying Stocks. We note that the Commission has acknowledged this type of correlation in connection with Rule 10a-1 relief granted to other index-based products such as SPDRs, MidCap SPDRs, DIAMONDS, Select Sector SPDRs, iShares and streetTracks.9 These products are, like the Biotech BOXES, securities whose value is directly linked to the market prices of the common stocks underlying an index approved by the Commission.10 Given the similarities in trading characteristics between these products and the Biotech BOXES, and in light of the factors set out below, it would not be appropriate or in the public interest to subject the Biotech BOXES to more stringent regulation, which would place them at a trading disadvantage relative to other comparable products.11
In addition, the calculation of the BTK Index according to the equal dollar method will ensure that any concentration of the weight of the Index in any Underlying Stock or group of Underlying Stocks will be temporary pending the next rebalancing. As described above, each Underlying Stock will represent an equal percentage of the BTK Index following each quarterly rebalancing of the Index.
Like many other index-linked products that have been granted relief from Rule 10a-1, trading in the Biotech BOXES will be subject to significant anti-manipulation standards included in the listing rules of both the Phlx and the Amex. These rules, which were subject to the prior approval of the Commission pursuant to Section 19(b)(1) of the Exchange Act and Rule 19b-4 thereunder, as well as ongoing review by the Commission, establish objective criteria for the composition of the BTK Index.12
Moreover, in the Section 19(b)(2) order approving the BTK Index, the Commission noted that the Amex's options listing standards, which are uniform among the options exchanges, provide that a security underlying an option must, among other requirements, meet substantial minimum thresholds of market capitalization and liquidity.13 It is noteworthy that, in its 1992 approval of the BTK Index, the Commission stated that the market capitalizations of the stocks underlying the index then ranged from a high of $8.6 billion to a low of $149.0 million, with the mean being $1.06 billion. By contrast, as of January 25, 2002, the market capitalization of the stocks underlying the BTK Index ranged from a high of $58.6 billion to a low of $1.1 billion, with the average being $10.1 billion. As of such date, the market capitalization of all such Underlying Stocks was approximately $171.3 billion, and the total number of shares outstanding of the Underlying Stocks ranged from approximately 50.6 million to 1.0 billion. The average daily trading volume of such Underlying Stocks during the period from November 23, 2001 to January 25, 2002 ranged from a low of approximately 613,770 to a high of 13.1 million shares per day. Moreover, in its Rule 19b-2 filing, the Amex states that in making replacement determinations, it "will make every effort to take into account a stock's capitalization, liquidity, volatility, and name recognition."14 Thus, each of the Underlying Stocks included in the BTK Index is now and is expected to continue to be an actively traded security within the meaning of Rule 101(c)(1) of Regulation M under the Exchange Act and will have a substantial market capitalization. The Biotech BOXES themselves must have a minimum public distribution of 150,000 BOXES at issuance and are expected to achieve an "ADTV" value (within the meaning of Regulation M) of at least $100,000 within 60 calendar days of their initial issuance.15
The depth of both the expected trading markets for the Biotech BOXES and of the existing trading markets for the Underlying Stocks makes the possibility of manipulation remote. The Commission has repeatedly recognized that the market prices of highly liquid securities are less susceptible to manipulation, including, for example, in the context of distributions subject to Regulation M.16 Indeed, in considering the continued effectiveness of Rule 10a-1 in its Concept Release regarding the Rule, the Commission requested comment whether an exception from Rule 10a-1 should be available for all highly liquid securities - assuming that the Rule is retained at all.17
Given the anticipated liquidity of the Biotech BOXES and the actual liquidity and market capitalization of the Underlying Stocks, an investor with manipulative intent would likely have to sell short a substantial amount of the Biotech BOXES to manipulate the price of a single Underlying Stock, and such short sales would be subject to applicable margin requirements. By making such short sales, the investor would be effectively selling short all of the Underlying Stocks. To remain economically neutral with respect to those Underlying Stocks not intended to be manipulated, the investor would have to purchase each of the 16 other Underlying Stocks, in proportion to their representation in the BTK Index. The expense, opportunity cost and impracticality of this strategy are apparent.
Even if short sales were able temporarily to depress the market price of the Biotech BOXES, Morgan Stanley Dean Witter believes that any disparities in relative market values between the Biotech BOXES and the Underlying Stocks would tend to be corrected immediately by arbitrage activity. The arbitrage opportunity is created as a result of the ability of holders of the Biotech BOXES to exchange their Biotech BOXES for the cash value of the Underlying Stocks on any trading day, as well as by the ability of Morgan Stanley Dean Witter to issue additional Biotech BOXES to satisfy market demand and maintain their liquidity. While it expects that series reopenings will occur no more frequently than monthly, Morgan Stanley Dean Witter intends to reopen the Biotech BOXES at any time in which a significant disparity exists in supply and demand, thereby reducing the opportunities to manipulate the market prices for the Biotech BOXES or the Underlying Stocks through short sales of the Biotech BOXES.18 Moreover, the ability of Morgan Stanley Dean Witter to issue additional Biotech BOXES provides investors with an opportunity analogous in respect of arbitrage to obtaining "Creation Units" of SPDRS and other similar products through the deposit of the relevant underlying stocks or "Deposit Securities."19 Under these circumstances, and in light of the ability of investors to exchange their Biotech BOXES on a daily basis for the cash value of the Underlying Stocks, it would appear to be economically futile to use short sales of Biotech BOXES to depress the market price(s) of any Underlying Stock(s).
The trading market for the Biotech BOXES would be adversely affected if Rule 10a-1 operated to prevent dealers or the designated primary market maker from making short sales of the Biotech BOXES to satisfy customer demand. Requiring an investor to utilize another means, such as index options, to achieve its investment goals would be detrimental to the market for the Biotech BOXES and contrary to the public interest in liquid, efficient securities markets.
Rule 14e-5 prohibits a person who makes a cash tender offer or exchange offer (an "Offer") for any equity security from directly or indirectly purchasing such security or any "related security,"20 except as part of the Offer from the time it is publicly announced until its expiration. The Rule also applies to the dealer-manager of the Offer, its affiliates and certain advisers thereto ("Covered Persons"). MS & Co. offers a full range of banking and securities services, including merger and acquisition advisory services. From time to time, MS & Co. or one of its affiliates may act as dealer-manager in connection with an Offer relating to an Underlying Stock (a "Subject Security") included in the Biotech BOXES.
We respectfully request that the Commission grant exemptive, interpretive or no-action relief from Rule 14e-5 to permit MS & Co. and any other Covered Person (including a member or member organization of the Phlx or the Amex) during such Offer to make purchases and arrangements to purchase a Subject Security or any "Related Security" (as defined in Rule 14e-5) with respect to a Subject Security (the "Trading Activities"), so long as (a) such activities are conducted in the ordinary course of such Covered Person's business solely to offset sales of the Biotech BOXES (including subsequent issuances of such Biotech BOXES) pursuant to bona fide hedging and covering activities; and (b) the other conditions specified below are satisfied.
With respect to purchases of a Subject Security made in connection with Trading Activities, we note that Rule 14e-5(b)(5) excepts purchases and arrangements to purchase baskets of securities that may contain a Subject Security subject to certain conditions, including that the basket contain at least 20 stocks and that the Subject Security not account for more than 5% of the value of the basket. In the Release adopting Rule 14e-5, the Commission stated that transactions in baskets meeting these terms would provide "little opportunity for a covered person to facilitate an offer or for a security holder to exact a premium from the offeror."21 The BTK Index would not currently meet the 20-stock minimum requirement and, under the Section 19(b)(2) order approving the BTK Index, a single Underlying Stock of the BTK Index may represent more than 5% of the value of the BTK Index. Accordingly, purchases of the Underlying Stocks relating to the BTK Index would not be eligible for the basket exception of Rule 14e-5(b)(5).
For the reasons set forth above, however, and in light of the Commission's previous grant of exemptive relief from Rule 14e-5 with respect to the Pharmaceutical BOXES, we believe that the imposition of these limitations is not appropriate in the case of the Biotech BOXES. As previously noted, the composition of the BTK Index is subject to anti-manipulative standards approved by the Commission. As demonstrated above, these standards, coupled with the exchange feature of the BOXES and the ability of Morgan Stanley Dean Witter to make subsequent issuances of the BOXES, operate to prevent investors from using derivative securities, such as the Biotech BOXES, to manipulate the market prices of either the Biotech BOXES or the Underlying Stocks.
In addition, the Trading Activities by their nature do not present the opportunity for the type of abuse Rule 14e-5 is designed to prevent. As stated above, Morgan Stanley Dean Witter anticipates that its affiliate, MS & Co., will make a market in the Biotech BOXES and will engage in purchases and sales of the Underlying Stocks or other instruments (including Related Securities) to offset exposure that it may incur in connection with its market-making activities. In addition, to the extent that it makes subsequent issuances of the Biotech BOXES to assure their liquidity, Morgan Stanley Dean Witter anticipates that MS & Co., as its hedge provider under the Biotech BOXES, will acquire Underlying Stocks or Related Securities to fully hedge its potential exposure to exchanges of such BOXES. In each case, the purchases will be made so as to remain market "neutral" or economically indifferent to whether the Underlying Stocks rise or fall in value relative to the market prices of the Biotech BOXES. This goal is plainly inconsistent with an intent to exact a premium from the offeror or to bid up the market price of the Subject Security. Moreover, the Commission has frequently acknowledged the importance of hedging activities in risk reduction, including for example in its adoption of Rule 11a1-3(T) under Section 11 of the Exchange Act, which provides that:
[a] bona fide hedge transaction effected on a national securities exchange . . . and involving a long or short position in a security entitling the holder to acquire or sell an equity security, and a long or short position in one or more other securities entitling the holder to acquire or sell such equity security, shall be deemed to be of a kind which is consistent with the purposes of Section 11(a)(1) of the [Exchange] Act, the protection of investors, and the maintenance of fair and orderly markets.22
All of the proposed hedging or covering activity will be conducted in the ordinary course of business of the relevant Covered Person and would not be conducted for the purpose of facilitating any Offer. Given the impracticality of using the Trading Activities for purposes of facilitating an Offer, application of Rule 14e-5 to prevent ordinary course market-making in the Biotech BOXES and related hedging would further no intended purpose of the Rule and would disrupt the trading market for the Biotech BOXES, harming, in particular, retail investors who look to dispose of their BOXES in a liquid secondary market. Any disruption would be significant, both with respect to the pricing efficiency of the Biotech BOXES and, to the extent reopenings of the Biotech BOXES were precluded, their liquidity. Accordingly, Morgan Stanley Dean Witter respectfully requests that MS & Co. and Morgan Stanley Dean Witter's other affiliates be granted an exemption from the provisions of Rule 14e-5 to engage in the Trading Activities with respect to the Biotech BOXES, subject to the following conditions:23
* * *
If you determine that you are unable to render the advice that we have requested, we would appreciate the opportunity to discuss our request with the staff prior to the issuance of a written response to this letter. We are available at your convenience to meet in person or by telephone for this purpose. Please contact the undersigned at (212) 225-2472 or James F. McMullin of this office at (212) 225-2336 if you have any questions.
Very truly yours,
Janet L. Fisher
cc: Larry E. Bergmann, Esq.,
Richard M. Bayus, II, Esq.,
John G. Saia, Esq.,
Martin M. Cohen, Esq.,
Georgia Bullitt, Esq.,
James F. McMullin, Esq.,